Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is a global healthcare company headquartered in Alameda, California, specializing in innovative interventional therapies. The company is renowned for developing and marketing medical devices aimed at treating complex medical conditions with significant unmet clinical needs. Penumbra's product portfolio includes neurovascular and peripheral vascular devices, which are primarily used by specialist physicians in hospitals.
Penumbra's neurovascular product line, which generates the majority of the company's revenue, includes technologies for neurovascular access, ischemic stroke treatment, neurovascular embolization, and neurosurgical tools. The peripheral vascular segment offers solutions for peripheral embolization and peripheral thrombectomy. These devices are designed to improve clinical outcomes, reduce procedural times and enhance patient safety, contributing to overall healthcare cost savings.
The company's innovations are supported by a strong commitment to clinical research. Notable achievements include the recent STRIKE-PE study results, which demonstrated the safety and efficacy of Penumbra's Indigo® Aspiration System with Lightning™ technology for treating pulmonary embolism (PE). This computer-assisted vacuum thrombectomy (CAVT) system significantly improved clinical and functional outcomes, such as reduced right heart strain and enhanced patient mobility.
Penumbra's financial performance reflects its robust market presence. For the third quarter of 2023, the company reported revenues of $270.9 million, a 26.8% increase compared to the previous year. The U.S. market accounted for 72% of this revenue, driven by strong sales of thrombectomy products. Gross profits rose to $177.7 million, highlighting the company's ability to leverage its product mix and production efficiencies.
Looking ahead, Penumbra remains focused on expanding its product portfolio and geographic presence. Recent milestones include the launch of Lightning Flash™ 2.0, an advanced CAVT system designed for faster thrombus removal with minimal blood loss. The company also started enrolling patients in the STORM-PE trial, a groundbreaking study comparing CAVT to standard anticoagulation therapy for PE treatment.
Penumbra's strategic vision includes continuous innovation, strengthening partnerships, and expanding its footprint in existing and new markets. The company supports healthcare providers in over 100 countries, ensuring a broad impact on global health outcomes through its cutting-edge medical technologies.
Rosen Law Firm is investigating potential securities claims for Penumbra shareholders due to allegations of misleading business information. This follows a series of negative reports, including a significant drop in share price by nearly 9% on December 8, 2020, after claims of falsified research. Additionally, a voluntary recall of the JET 7 Xtra Flex catheter led to a 7.3% decline in the stock's price the next day. The firm aims to prepare a securities lawsuit to protect investor interests.
Penumbra, Inc. (NYSE: PEN) released preliminary revenue results for Q4 and FY 2020, highlighting a projected fourth quarter revenue of $162.5 to $167.9 million, reflecting a 12% to 16% increase year-over-year. Excluding a voluntary recall impact, non-GAAP revenue for Q4 is estimated at $172.5 to $172.9 million, a 19% growth. Full-year revenue is expected between $556.0 and $561.4 million, up 2% to 3% from 2019. Vascular product sales are projected to grow significantly, while neuro product sales are estimated to decline by 11% to 13% for the year.
Penumbra recalls JET 7 Xtra Flex Catheters on December 15, 2020, due to susceptibility to distal tip damage. This issue may lead to potential vessel damage and serious patient injury or death during use. The company advises healthcare professionals to review the full recall advisory on their website. They will also hold a conference call on the same day to discuss details surrounding this voluntary recall, which could impact their market reputation and financial stability.
On December 8, 2020, Penumbra, Inc. (NYSE: PEN) issued a statement addressing false claims made by short sellers regarding scientific research by co-founder Dr. Arani Bose. The company confirmed that allegations about misattributed research are inaccurate. CEO Adam Elsesser spoke with Bank of America analyst Bob Hopkins, reaffirming the integrity of the Penumbra JET 7 Reperfusion Catheter and emphasizing compliance with Quality System Regulations. Penumbra reported no patient deaths linked to the catheter when used properly and is considering further actions against the allegations.
Penumbra, Inc. (NYSE: PEN) has announced that its CEO will participate in a discussion with Bank of America on December 8, 2020, at 8:30 AM ET. The event will focus on the company's innovative healthcare therapies. An audio webcast will be accessible on the company’s website for at least two weeks post-event. Based in Alameda, California, Penumbra specializes in developing and marketing products addressing significant medical needs in healthcare markets worldwide.
Penumbra, Inc. (NYSE: PEN) received FDA 510(k) clearance for the expanded indications of its Indigo® Aspiration System, including the Lightning™ 12 catheter. This system is now approved for removing fresh emboli and thrombi from peripheral arteries and veins, and for treating pulmonary embolism (PE), a condition that has risen during the COVID-19 pandemic. Lightning 12's advanced technology improves clot detection and removal efficacy. The system was launched in July and is available for immediate use, aiming to reduce the need for thrombolytics and associated ICU stays.
Penumbra, Inc. (NYSE: PEN) has announced a partnership with RapidAI to enhance clinical decision-making for pulmonary embolism (PE) diagnosis. This collaboration aims to develop AI-driven modules that streamline triage and improve the interpretation of CT scans. The initiative is timely, considering the challenges posed by the COVID-19 pandemic. Penumbra's Indigo® System, recently launched for blood clot removal, aligns with its commitment to addressing unmet clinical needs. The partnership is expected to increase awareness and treatment options for PE, a critical healthcare issue.
Penumbra, Inc. (NYSE: PEN) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 1:30 PM ET (10:30 AM PT). The event will showcase the company's innovative healthcare solutions. Interested parties can access a webcast of the presentation through the company's website, available for two weeks post-event. Penumbra specializes in designing and market-leading products for challenging medical conditions, primarily serving U.S., Europe, Canada, and Australia.
Penumbra, Inc. (NYSE: PEN) reported third-quarter 2020 financials, revealing a revenue increase of 8.3% to $151.1 million compared to the same period in 2019. US revenue surged 22% to $109.7 million. However, neuro product sales declined by 8.8%, totaling $75.9 million, while vascular product sales rose 33.6% to $75.2 million. Operating loss stood at $20.2 million, impacted by one-time personnel expenses related to the Lightning product launch. The ongoing COVID-19 pandemic continues to create uncertainty in business performance.
Penumbra, Inc. (NYSE: PEN) will hold a conference call on October 28, 2020, at 4:30 PM ET to discuss its Q3 2020 financial results. The call will occur after market close, and a press release with the financial results will be available at that time. This initiative highlights Penumbra's support for democracy by designating Election Day 2020 as a paid holiday for U.S. employees. Investors can access the call by phone or via a webcast on the company’s website.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
What does Penumbra, Inc. specialize in?
What are Penumbra's key product categories?
How does Penumbra's technology improve patient outcomes?
What recent clinical study results have Penumbra announced?
What financial performance did Penumbra report for Q3 2023?
How is Penumbra expanding its product portfolio?
What is the focus of the STORM-PE trial?
Which regions contribute to Penumbra's revenue?
What are Penumbra's future growth strategies?
Where can more information about Penumbra be found?
